TransThera Sciences (Nanjing). Inc.HKEX: 2617

Next Day Disclosure Return

Oct 27, 2026 at 6:50 AM EDT · Issued by TransThera Sciences (Nanjing). Inc. via HKEXnews

Filed with HKEX · Stock code 2617 · Oct 27, 2026 at 6:50 AM EDT

On 6ix: 6ix.com/news/next-day-disclosure-return-1694

View Attachment

6ix is reading this filing.

View original source (HKEXnews)TransThera Sciences (Nanjing). Inc. on 6ix

Earlier from TransThera Sciences (Nanjing)

Inside information announcement issuance of the filing notice by the csrc for the h share full circulation by the companyOct 26
Voluntary announcement business update on commercialisation of core product yochanraOct 22
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026Oct 5
Interim report 2026Sep 21
Voluntary announcement first patient dosed in phase II clinical trial of tinengotinib in combination with novel hormonal therapy for pretreated and progressed metastatic castration-resistant prostate cancer in ChinaSep 18

Later from TransThera Sciences (Nanjing)

Inside information announcement grant of listing approval by the stock exchange for implementation of the h share full circulationNov 1

All TransThera Sciences (Nanjing) news releases

Follow TransThera Sciences (Nanjing) into a list and get an email when it puts out news.

Follow TransThera Sciences (Nanjing)